|
1
|
Husain AN, Colby T, Ordonez N, Krausz T,
Attanoos R, Beasley MB, Borczuk AC, Butnor K, Cagle PT, Chirieac
LR, et al: Guidelines for pathologic diagnosis of malignant
mesothelioma: 2012 update of the consensus statement from the
International Mesothelioma Interest Group. Arch Pathol Lab Med.
137:647–667. 2013.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Bridda A, Padoan I, Mencarelli R and Frego
M: Peritoneal mesothelioma: A review. MedGenMed.
9(32)2007.PubMed/NCBI
|
|
3
|
Teta MJ, Mink PJ, Lau E, Sceurman BK and
Foster ED: US mesothelioma patterns 1973-2002: Indicators of change
and insights into background rates. Eur J Cancer Prev. 17:525–534.
2008.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Selikoff IJ, Hammond EC and Seidman H:
Latency of asbestos disease among insulation workers in the United
States and Canada. Cancer. 46:2736–2740. 1980.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Moolgavkar SH, Meza R and Turim J: Pleural
and peritoneal mesotheliomas in SEER: Age effects and temporal
trends, 1973-2005. Cancer Causes Control. 20:935–944.
2009.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Travis WD, Brambilla E, Nicholson AG,
Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E,
Flieder DB, et al: The 2015 World Health Organization
Classification of Lung Tumors: Impact of Genetic, Clinical and
Radiologic Advances Since the 2004 Classification. J Thorac Oncol.
10:1243–1260. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Beebe-Dimmer JL, Fryzek JP, Yee CL, Dalvi
TB, Garabrant DH, Schwartz AG and Gadgeel S: Mesothelioma in the
United States: A surveillance, epidemiology, and end results
(SEER)-Medicare investigation of treatment patterns and overall
survival. Clin Epidemiol. 8:743–750. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ullah A, Waheed A, Khan J, Mishra A,
Tareen B, Nama N, Karki NR, Panezai MS, Zarate LV, White J, et al:
Incidence, survival analysis and future perspective of primary
peritoneal mesothelioma (PPM): A population-based study from SEER
Database. Cancers (Basel). 14(942)2022.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kaya H, Sezgı C, Tanrıkulu AC, Taylan M,
Abakay O, Sen HS, Abakay A, Kucukoner M and Kapan M: Prognostic
factors influencing survival in 35 patients with malignant
peritoneal mesothelioma. Neoplasma. 61:433–438. 2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Antman KH: Clinical presentation and
natural history of benign and malignant mesothelioma. Semin Oncol.
8:313–320. 1981.PubMed/NCBI
|
|
11
|
Sugarbaker PH: Update on the management of
malignant peritoneal mesothelioma. Transl Lung Cancer Res.
7:599–608. 2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Turaga KK, Deraco M and Alexander HR:
Current management strategies for peritoneal mesothelioma. Int J
Hyperthermia. 33:579–581. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Gazivoda VP, Kangas-Dick AW, Greenbaum AA,
Roshal J, Chen C, Moore DF, Langan RC, Kennedy TJ, Minerowicz C and
Alexander HR: Expression of PD-L1 in patients with malignant
peritoneal mesothelioma: A pilot study. J Surg Res. 277:131–137.
2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Judge S, Thomas P, Govindarajan V, Sharma
P and Loggie B: Malignant Peritoneal Mesothelioma: Characterization
of the inflammatory response in the tumor microenvironment. Ann
Surg Oncol. 23:1496–1500. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Tazzari M, Brich S, Tuccitto A, Bozzi F,
Beretta V, Spagnuolo RD, Negri T, Stacchiotti S, Deraco M, Baratti
D, et al: Complex Immune Contextures Characterise Malignant
Peritoneal Mesothelioma: Loss of adaptive immunological signature
in the more aggressive histological types. J Immunol Res.
2018(5804230)2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Chapel DB, Stewart R, Furtado LV, Husain
AN, Krausz T and Deftereos G: Tumor PD-L1 expression in malignant
pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and
Dako PD-L1 28-8 pharmDx assays. Hum Pathol. 87:11–17.
2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
White MG, Schulte JJ, Xue L, Berger Y,
Schuitevoerder D, Vining CC, Kindler HL, Husain A, Turaga KK and
Eng OS: Heterogeneity in PD-L1 expression in malignant peritoneal
mesothelioma with systemic or intraperitoneal chemotherapy. Br J
Cancer. 124:564–566. 2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Le DT, Uram JN, Wang H, Bartlett BR,
Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et
al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl
J Med. 372:2509–2520. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Palmieri G, Colombino M, Cossu A,
Marchetti A, Botti G and Ascierto PA: Genetic instability and
increased mutational load: Which diagnostic tool best direct
patients with cancer to immunotherapy? J Transl Med.
15(17)2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Jamieson NB and Maker AV: Gene-expression
profiling to predict responsiveness to immunotherapy. Cancer Gene
Ther. 24:134–140. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Chalmers ZR, Connelly CF, Fabrizio D, Gay
L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J,
et al: Analysis of 100,000 human cancer genomes reveals the
landscape of tumor mutational burden. Genome Med.
9(34)2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Chang L, Chang M, Chang HM and Chang F:
Microsatellite instability: A predictive biomarker for cancer
immunotherapy. Appl Immunohistochem Mol Morphol. 26:e15–e21.
2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Le DT, Durham JN, Smith KN, Wang H,
Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et
al: Mismatch repair deficiency predicts response of solid tumors to
PD-1 blockade. Science. 357:409–413. 2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Overman MJ, McDermott R, Leach JL, Lonardi
S, Lenz H-J, Morse MA, Desai J, Hill A, Axelson M, Moss RA, et al:
Nivolumab in patients with metastatic DNA mismatch repair-deficient
or microsatellite instability-high colorectal cancer (CheckMate
142): An open-label, multicentre, phase 2 study. Lancet Oncol.
18:1182–1191. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Overman MJ, Lonardi S, Wong KYM, Lenz HJ,
Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill
A, et al: Durable clinical benefit with nivolumab plus ipilimumab
in DNA mismatch repair-deficient/microsatellite instability-high
metastatic colorectal cancer. J Clin Oncol. 36:773–779.
2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Imai K and Yamamoto H: Carcinogenesis and
microsatellite instability: The interrelationship between genetics
and epigenetics. Carcinogenesis. 29:673–680. 2008.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Watson P and Lynch HT: The tumor spectrum
in HNPCC. Anticancer Res. 14 (4B):1635–1639. 1994.PubMed/NCBI
|
|
28
|
Bonneville R, Krook MA, Kautto EA, Miya J,
Wing MR, Chen HZ, Reeser JW, Yu L and Roychowdhury S: Landscape of
microsatellite instability across 39 cancer types. JCO Precis
Oncol. 2017(PO.17.00073)2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Rizvi NA, Hellmann MD, Snyder A, Kvistborg
P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al: Cancer
immunology. Mutational landscape determines sensitivity to PD-1
blockade in non-small cell lung cancer. Science. 348:124–128.
2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Johnson DB, Frampton GM, Rioth MJ, Yusko
E, Xu Y, Guo X, Ennis RC, Fabrizio D, Chalmers ZR, Greenbowe J, et
al: Targeted next generation sequencing identifies markers of
response to PD-1 Blockade. Cancer Immunol Res. 4:959–967.
2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Shao C, Li G, Huang L, Pruitt S,
Castellanos E, Frampton G, Carson KR, Snow T, Singal G, Fabrizio D,
et al: Prevalence of high tumor mutational burden and association
with survival in patients with less common solid tumors. JAMA Netw
Open. 3(e2025109)2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Yamada N, Oizumi S, Kikuchi E, Shinagawa
N, Konishi-Sakakibara J, Ishimine A, Aoe K, Gemba K, Kishimoto T,
Torigoe T and Nishimura M: CD8+ tumor-infiltrating lymphocytes
predict favorable prognosis in malignant pleural mesothelioma after
resection. Cancer Immunol Immunother. 59:1543–1549. 2010.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Anraku M, Cunningham KS, Yun Z, Tsao MS,
Zhang L, Keshavjee S, Johnston MR and de Perrot M: Impact of
tumor-infiltrating T cells on survival in patients with malignant
pleural mesothelioma. J Thorac Cardiovasc Surg. 135:823–829.
2008.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Thapa B, Walkeiwicz M, Rivalland G, Murone
C, Asadi K, Barnett S, Knight S, Hendry S, Russell P and John T:
OA08.05 quantifying tumour infiltrating lymphocytes (TILs) in
malignant pleural mesothelioma (MPM)-defining the hot, the warm and
the cold tumours. J Thorac Oncol. 13(S339)2018.
|
|
35
|
Galon J, Mlecnik B, Bindea G, Angell HK,
Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, et
al: Towards the introduction of the ‘Immunoscore’ in the
classification of malignant tumours. J Pathol. 232:199–209.
2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Donnem T, Kilvaer TK, Andersen S,
Richardsen E, Paulsen EE, Hald SM, Al-Saad S, Brustugun OT, Helland
A, Lund-Iversen M, et al: Strategies for clinical implementation of
TNM-Immunoscore in resected nonsmall-cell lung cancer. Ann Oncol.
27:225–232. 2016.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Hendry S, Salgado R, Gevaert T, Russell
PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV,
Gonzalez-Ericsson PI, et al: Assessing tumor-infiltrating
lymphocytes in solid tumors: A practical review for pathologists
and proposal for a standardized method from the International
Immunooncology Biomarkers Working Group: Part 1: Assessing the host
immune response, TILs in invasive breast carcinoma and ductal
carcinoma in situ, metastatic tumor deposits and areas for further
research. Adv Anat Pathol. 24:235–251. 2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012.PubMed/NCBI View
Article : Google Scholar
|
|
39
|
Spranger S, Spaapen RM, Zha Y, Williams J,
Meng Y, Ha TT and Gajewski TF: Up-regulation of PD-L1, IDO, and
T(regs) in the melanoma tumor microenvironment is driven by CD8(+)
T cells. Sci Transl Med. 5(200ra116)2013.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Hegmans JP, Hemmes A, Hammad H, Boon L,
Hoogsteden HC and Lambrecht BN: Mesothelioma environment comprises
cytokines and T-regulatory cells that suppress immune responses.
Eur Respir J. 27:1086–1095. 2006.PubMed/NCBI View Article : Google Scholar
|
|
41
|
DeLong P, Carroll RG, Henry AC, Tanaka T,
Ahmad S, Leibowitz MS, Sterman DH, June CH, Albelda SM and
Vonderheide RH: Regulatory T cells and cytokines in malignant
pleural effusions secondary to mesothelioma and carcinoma. Cancer
Biol Ther. 4:342–346. 2005.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Meloni F, Morosini M, Solari N, Passadore
I, Nascimbene C, Novo M, Ferrari M, Cosentino M, Marino F, Pozzi E
and Fietta AM: Foxp3 expressing CD4+ CD25+ and CD8+CD28- T
regulatory cells in the peripheral blood of patients with lung
cancer and pleural mesothelioma. Hum Immunol. 67:1–12.
2006.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Kojima M, Kajino K, Momose S, Wali N,
Hlaing MT, Han B, Yue L, Abe M, Fujii T, Ikeda K and Hino O:
Possible reversibility between epithelioid and sarcomatoid types of
mesothelioma is independent of ERC/mesothelin expression. Respir
Res. 21(187)2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Brabletz T, Kalluri R, Nieto MA and
Weinberg RA: EMT in cancer. Nat Rev Cancer. 18:128–134.
2018.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Aiello NM and Kang Y: Context-dependent
EMT programs in cancer metastasis. J Exp Med. 216:1016–1026.
2019.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Dongre A and Weinberg RA: New insights
into the mechanisms of epithelial-mesenchymal transition and
implications for cancer. Nat Rev Mol Cell Biol. 20:69–84.
2019.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Terry S, Savagner P, Ortiz-Cuaran S,
Mahjoubi L, Saintigny P, Thiery JP and Chouaib S: New insights into
the role of EMT in tumor immune escape. Mol Oncol. 11:824–846.
2017.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Taki M, Abiko K, Ukita M, Murakami R,
Yamanoi K, Yamaguchi K, Hamanishi J, Baba T, Matsumura N and Mandai
M: Tumor Immune Microenvironment during Epithelial-Mesenchymal
Transition. Clin Cancer Res. 27:4669–4679. 2021.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Salazar Y, Zheng X, Brunn D, Raifer H,
Picard F, Zhang Y, Winter H, Guenther S, Weigert A, Weigmann B, et
al: Microenvironmental Th9 and Th17 lymphocytes induce metastatic
spreading in lung cancer. J Clin Invest. 130:3560–3575.
2020.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Blum Y, Meiller C, Quetel L, Elarouci N,
Ayadi M, Tashtanbaeva D, Armenoult L, Montagne F, Tranchant R,
Renier A, et al: Dissecting heterogeneity in malignant pleural
mesothelioma through histo-molecular gradients for clinical
applications. Nat Commun. 10(1333)2019.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Wu L, Amjad S, Yun H, Mani S and de Perrot
M: A panel of emerging EMT genes identified in malignant
mesothelioma. Sci Rep. 12(1007)2022.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Raghav K, Liu S, Overman MJ, Willett AF,
Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, et al:
Efficacy, safety, and biomarker analysis of combined PD-L1
(atezolizumab) and VEGF (bevacizumab) blockade in advanced
malignant peritoneal mesothelioma. Cancer Discov. 11:2738–2747.
2021.PubMed/NCBI View Article : Google Scholar
|
|
54
|
de Reyniès A, Jaurand MC, Renier A, Couchy
G, Hysi I, Elarouci N, Galateau-Sallé F, Copin MC, Hofman P, Cazes
A, et al: Molecular classification of malignant pleural
mesothelioma: Identification of a poor prognosis subgroup linked to
the epithelial-to-mesenchymal transition. Clin Cancer Res.
20:1323–1334. 2014.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Baumann F, Flores E, Napolitano A, Kanodia
S, Taioli E, Pass H, Yang H and Carbone M: Mesothelioma patients
with germline BAP1 mutations have 7-fold improved long-term
survival. Carcinogenesis. 36:76–81. 2015.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Kaszuba MC, Pulido JS, Folpe AL, Pichurin
PN, Goodenberger ML and Spinner RJ: Malignant peripheral nerve
sheath tumor in a Patient with BAP1 tumor predisposition syndrome.
World Neurosurg. 109:362–364. 2018.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Shrestha R, Nabavi N, Lin YY, Mo F,
Anderson S, Volik S, Adomat HH, Lin D, Xue H, Dong X, et al: BAP1
haploinsufficiency predicts a distinct immunogenic class of
malignant peritoneal mesothelioma. Genome Med. 11(8)2019.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Vogelzang NJ, Rusthoven JJ, Symanowski J,
Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S,
Manegold C, et al: Phase III study of pemetrexed in combination
with cisplatin versus cisplatin alone in patients with malignant
pleural mesothelioma. J Clin Oncol. 21:2636–2644. 2003.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Jänne PA, Wozniak AJ, Belani CP, Keohan
ML, Ross HJ, Polikoff JA, Mintzer DM, Taylor L, Ashland J, Ye Z, et
al: Open-label study of pemetrexed alone or in combination with
cisplatin for the treatment of patients with peritoneal
mesothelioma: Outcomes of an expanded access program. Clin Lung
Cancer. 7:40–46. 2005.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Carteni G, Manegold C, Garcia GM, Siena S,
Zielinski CC, Amadori D, Liu Y, Blatter J, Visseren-Grul C and
Stahel R: Malignant peritoneal mesothelioma-Results from the
International Expanded Access Program using pemetrexed alone or in
combination with a platinum agent. Lung Cancer. 64:211–218.
2009.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Castagneto B, Botta M, Aitini E, Spigno F,
Degiovanni D, Alabiso O, Serra M, Muzio A, Carbone R, Buosi R, et
al: Phase II study of pemetrexed in combination with carboplatin in
patients with malignant pleural mesothelioma (MPM). Ann Oncol.
19:370–373. 2008.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Ceresoli GL, Zucali PA, Favaretto AG,
Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E,
Cavina R, et al: Phase II study of pemetrexed plus carboplatin in
malignant pleural mesothelioma. J Clin Oncol. 24:1443–1448.
2006.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Santoro A, O'Brien ME, Stahel RA,
Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom
S, Liu Y, et al: Pemetrexed plus cisplatin or pemetrexed plus
carboplatin for chemonaïve patients with malignant pleural
mesothelioma: Results of the International Expanded Access Program.
J Thorac Oncol. 3:756–763. 2008.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Zalcman G, Mazieres J, Margery J,
Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre
R, Monnet I, Gounant V, et al: Bevacizumab for newly diagnosed
pleural mesothelioma in the Mesothelioma Avastin Cisplatin
Pemetrexed Study (MAPS): A randomised, controlled, open-label,
phase 3 trial. Lancet. 387:1405–1414. 2016.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Hassan R, Thomas A, Nemunaitis JJ, Patel
MR, Bennouna J, Chen FL, Delord JP, Dowlati A, Kochuparambil ST,
Taylor MH, et al: Efficacy and safety of avelumab treatment in
patients with advanced unresectable mesothelioma: Phase 1b results
from the JAVELIN solid tumor trial. JAMA Oncol. 5:351–357.
2019.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Fennell DA, Ewings S, Ottensmeier C,
Califano R, Hanna GG, Hill K, Danson S, Steele N, Nye M, Johnson L,
et al: Nivolumab versus placebo in patients with relapsed malignant
mesothelioma (CONFIRM): A multicentre, double-blind, randomised,
phase 3 trial. Lancet Oncol. 22:1530–1540. 2021.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Popat S, Curioni-Fontecedro A, Dafni U,
Shah R, O'Brien M, Pope A, Fisher P, Spicer J, Roy A, Gilligan D,
et al: A multicentre randomised phase III trial comparing
pembrolizumab versus single-agent chemotherapy for advanced
pre-treated malignant pleural mesothelioma: The European Thoracic
Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann Oncol.
31:1734–1745. 2020.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Maio M, Scherpereel A, Calabrò L, Aerts J,
Perez SC, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, et
al: Tremelimumab as second-line or third-line treatment in relapsed
malignant mesothelioma (DETERMINE): A multicentre, international,
randomised, double-blind, placebo-controlled phase 2b trial. Lancet
Oncol. 18:1261–1273. 2017.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Desai A, Karrison T, Rose B, Pemberton E,
Hill B, Straus CM, Tan Y-HC, Seiwert TY and Kindler HL: Phase II
trial of pembrolizumab (P) in patients (pts) with
previously-treated mesothelioma (MM). J Clin Oncol. 36 (Suppl
15)(S8565)2018.
|
|
70
|
Marmarelis ME, Wang X, Roshkovan L, Walker
S, McNulty S, Ciunci CA, Muira J, Katz SI, Cengel KA, et al:
Real-world outcomes of pembrolizumab in peritoneal mesothelioma. J
Clin Oncol. 38 (Suppl 15)(e21094)2020.
|
|
71
|
Peters S, Scherpereel A, Cornelissen R,
Oulkhouir Y, Greillier L, Kaplan MA, Talbot T, Monnet I, Hiret S,
Baas P, et al: First-line nivolumab plus ipilimumab versus
chemotherapy in patients with unresectable malignant pleural
mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol.
33:488–499. 2022.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Calabrò L, Rossi G, Morra A, Rosati C,
Cutaia O, Daffinà MG, Altomonte M, Di Giacomo AM, Casula M, Fazio
C, et al: Tremelimumab plus durvalumab retreatment and 4-year
outcomes in patients with mesothelioma: A follow-up of the open
label, non-randomised, phase 2 NIBIT-MESO-1 study. Lancet Respir
Med. 9:969–976. 2021.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Calabrò L, Morra A, Giannarelli D, Amato
G, D'Incecco A, Covre A, Lewis A, Rebelatto MC, Danielli R,
Altomonte M, et al: Tremelimumab combined with durvalumab in
patients with mesothelioma (NIBIT-MESO-1): An open-label,
non-randomised, phase 2 study. Lancet Respir Med. 6:451–460.
2018.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Raghav K, Liu S, Overman M, Morani A,
Willette A, Fournier K and Varadhachary G: Clinical efficacy of
immune checkpoint inhibitors in patients with advanced malignant
peritoneal mesothelioma. JAMA Netw Open. 4(e2119934)2021.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Forde PM, Anagnostou V, Sun Z, Dahlberg
SE, Kindler HL, Niknafs N, Purcell T, Santana-Davila R, Dudek AZ,
Borghaei H, et al: Durvalumab with platinum-pemetrexed for
unresectable pleural mesothelioma: Survival, genomic and
immunologic analyses from the phase 2 PrE0505 trial. Nat Med.
27:1910–1920. 2021.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Foote MB, Shia J, Zauderer MG, Nash GM and
Cercek A: Treatment of platinum nonresponsive metastatic malignant
peritoneal mesothelioma with combination chemoimmunotherapy. J
Immunother. 45:100–103. 2022.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Scagliotti GV, Gaafar R, Nowak AK, Nakano
T, van Meerbeeck J, Popat S, Vogelzang NJ, Grosso F, Aboelhassan R,
Jakopovic M, et al: Nintedanib in combination with pemetrexed and
cisplatin for chemotherapy-naive patients with advanced malignant
pleural mesothelioma (LUME-Meso): A double-blind, randomised,
placebo-controlled phase 3 trial. Lancet Respir Med. 7:569–580.
2019.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Bijelic L, Darcy K, Stodghill J, Tian C
and Cannon T: Predictors and outcomes of surgery in peritoneal
mesothelioma: An analysis of 2000 patients from the National cancer
database. Ann Surg Oncol. 27:2974–2982. 2020.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Thompson JC, Hwang WT, Davis C, Deshpande
C, Jeffries S, Rajpurohit Y, Krishna V, Smirnov D, Verona R,
Lorenzi MV, et al: Gene signatures of tumor inflammation and
epithelial-to-mesenchymal transition (EMT) predict responses to
immune checkpoint blockade in lung cancer with high accuracy. Lung
Cancer. 139:1–8. 2020.PubMed/NCBI View Article : Google Scholar
|
|
80
|
de Boer NL, van Kooten JP, Burger JWA,
Verhoef C, Aerts JGJV and Madsen EVE: Adjuvant dendritic cell based
immunotherapy (DCBI) after cytoreductive surgery (CRS) and
hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal
mesothelioma, a phase II single centre open-label clinical trial:
Rationale and design of the MESOPEC trial. BMJ Open.
9(e026779)2019.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Adusumilli PS, Zauderer MG, Rivière I,
Solomon SB, Rusch VW, O'Cearbhaill RE, Zhu A, Cheema W, Chintala
NK, Halton E, et al: A Phase I Trial of Regional
Mesothelin-Targeted CAR T-cell therapy in patients with malignant
pleural disease, in combination with the Anti-PD-1 Agent
Pembrolizumab. Cancer Discov. 11:2748–2763. 2021.PubMed/NCBI View Article : Google Scholar
|
